News

Exciting Phase 2 Results of Evorpacept Presentation at ASCO

Exciting Phase 2 Results of Evorpacept Presentation at ASCO

ALX Oncology's Promising Presentation of Evorpacept Results

ALX Oncology Holdings Inc. is generating excitement in the oncology community with the announcement of updated results from its Phase 2 ASPEN-06 clinical trial. This pivotal study highlights the potential of evorpacept, an innovative treatment designed to enhance the immune system's ability to combat cancer, specifically targeting HER2-positive gastric cancer. The results have been accepted for oral presentation at the prestigious American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium.

Details of the ASPEN-06 Clinical Trial

ASPEN-06 is a well-structured, multi-center trial that systematically evaluates the effectiveness of evorpacept in conjunction with other established treatments. This clinical trial focuses on patients suffering from HER2-positive gastric and gastroesophageal junction cancer, particularly those who have previously undergone anti-HER2 therapies.

What is Evorpacept?

Evorpacept is a groundbreaking investigational therapeutic developed by ALX Oncology. Uniquely, it combines a high-affinity CD47-targeting domain with an inactivated proprietary Fc domain, marking a significant advancement in targeting myeloid checkpoints in cancer therapy. In this trial, evorpacept is administered alongside trastuzumab and CYRAMZA® (ramucirumab) as well as paclitaxel, also known as TRP therapy.

Insights from the Upcoming Presentation

The oral presentation will feature a comprehensive analysis of the trial's outcomes, underlining the importance of evorpacept in redefining treatment protocols for HER2-positive gastric cancer. The presentation, to be directed by Dr. Kohei Shitara, a notable expert in the field, is set for January 23, 2025. This session is expected to draw significant interest as it could influence treatment approaches and patient outcomes in this challenging disease area.

Presentation Specifics

Dr. Shitara will present the final analysis of this randomized Phase 2 part of the ASPEN-06 study during the Rapid Oral Abstract Session A. Attendees can expect an insightful discussion on how evorpacept interacts with established therapies, potentially leading to improved patient care in the face of aggressive cancer types.

What’s Next for ALX Oncology?

As ALX Oncology continues to advance its clinical trials, the company remains dedicated to the mission of enhancing cancer care through innovative therapies. Evorpacept's promising results reflect ALX Oncology's commitment to improving the overall prognosis for patients with difficult-to-treat cancers. The company actively explores various cancer indications to refine therapeutic strategies and improve patient outcomes.

Keeping Stakeholders Informed

Following the oral presentation at ASCO, ALX Oncology will make detailed copies of the presentation available in the Publications section of its official website. This transparency is designed to keep healthcare professionals and investors informed about the latest advancements and findings from the company's clinical trials.

About ALX Oncology

ALX Oncology (NASDAQ: ALXO) is making strides as a clinical-stage biotechnology firm focused on developing therapies that harness the immune system against cancerous cells. Its flagship product, evorpacept, stands out as a potential key player in the immuno-oncology landscape. Clear evidence of its therapeutic possibilities rests on the ongoing clinical trials aimed at various cancer types. As the company progresses, they are eager to share updates and findings that could significantly impact cancer care and patients' lives.

Frequently Asked Questions

What is the ASPEN-06 clinical trial about?

The ASPEN-06 trial investigates the efficacy of evorpacept combined with other therapies for treating HER2-positive gastric cancer.

When will the results from the trial be presented?

The results will be presented on January 23, 2025, at the ASCO Gastrointestinal Cancers Symposium.

Who is presenting the trial results?

Dr. Kohei Shitara, a leading expert in gastrointestinal oncology, will present the findings from the trial.

Why is evorpacept significant in cancer therapy?

Evorpacept represents a novel approach to targeting myeloid checkpoints, offering hope for improved treatment outcomes in patients with aggressive cancers.

Where can I find more information about ALX Oncology?

More information about ALX Oncology and its therapies can be found on their official website and LinkedIn page.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

AHN Healthcare@Home Celebrates Fourth Top Workplace Win

Updated Category News Views 4

Four-Time Top Workplace Champ You want to talk consistency? Let's talk about AHN Healthcare@Home pulling in that Pittsburgh Top Workplace award four years running. It's no small feat, especially in the healthcare sector where employee burnout isn't just a buzzword—it's a daily challenge. How did a home health and hospice outfit like AHN land this honor? Well, it's all...

Continue Reading
Gray's Rise in ENR Rankings Highlights Sector Dominance

Updated Category News Views 5

Gray's Outstanding Reputation in the Construction Arena Nothing says “we're on top of our game” like snatching top slots in industry rankings, and that's precisely what Gray, the construction and engineering heavyweight, has managed to do. This firm recently secured impressive spots across ten different categories in the prestigious Engineering News-Record (ENR) Top...

Continue Reading
LifeLabs' AI Program: A Manager's New Toolbox

Updated Category News Views 4

Management In the Age of AI: New Frontiers Gone are the days when a simple software update meant staying competitive. We're in a new era, folks—one where AI isn't just a handy tool—it's reshaping entire industries. But here's the kicker: all the fancy tech in the world won't do squat without savvy managers who know how to drive adoption. Yup, that's the naked truth,...

Continue Reading
Celina Graves Joins Expanding GoLive Streamers Platform

Updated Category News Views 3

Celina Graves Breaks New Ground on GoLive Streamers You'd think television capture all the talent buzz, but nope. Celina Graves, known from her semifinalist run on America's Got Talent, is diving into new waters by joining GoLive Streamers. She's stirring up the scene by making her performances more personal, stretching beyond the flatness of your typical TV appearance....

Continue Reading
Schweid & Sons Reveals New Marinated Steak Tips Line

Updated Category News Views 4

No More Prep Dilemmas: Schweid & Sons Unveils Steak Tips Packing a punch in the protein aisle, Schweid & Sons throws down the gauntlet with their latest culinary innovation — Marinated Steak Tips. These aren't just your run-of-the-mill cuts, folks. We're talking premium Tri-Tip, butcher-trimmed to perfection, and marinated in both Cajun and Teriyaki styles. It's all...

Continue Reading
Primrose Schools App: A Bold Step for Digital Literacy

Updated Category News Views 4

Primrose Schools Delivers a New Era in Child Education Sitting at a crossroads between the tactile charm of hands-on learning and the inevitable march of digital literacy, Primrose Schools has unveiled something that might just rock the boat in early education: their new Balanced Learning® App. This move by Primrose comes at a crucial time when many parents are...

Continue Reading
Janitorial Wages Soar 26.7% Amid High Annual Openings

Updated Category News Views 3

Janitorial Sector Faces Wage Surge and Employment Shifts Look, if you thought the world of janitorial work was all brooms and mops without a paycheck edge, think again. From 2020 to 2025, wages for janitors and building cleaners didn't just tip-toe up the ladder—they practically sprinted, climbing 26.7%. BLS data laid this one out, with hourly pay shooting from $13.98...

Continue Reading
Craig Hospital Expands: A Milestone for Rehab Care

Updated Category News Views 6

A Bold Step Forward in Neurorehabilitation Over a September sky in Englewood, Colorado, a ceremonial beam rose, marking a major milestone for Craig Hospital. It's not just steel and concrete; it's hope and progress for many who've found themselves at the mercy of neurological injuries. Celebrating the 'topping out' of their expanded campus, Craig's latest step forward...

Continue Reading
Alito's Recusal: Supreme Court Climate Case Shaker

Updated Category News Views 8

Justice Alito Bows Out from A High-Stakes Climate Battle September 28, 2026, marked a notable turn in the legal landscape. Supreme Court Justice Samuel Alito chose to step away from a case that's got every investor, lawyer, and policy wonk on the edge of their seats—Suncor v. Boulder. This isn't about just any old courtroom squabble; it's a landmark climate case poised...

Continue Reading
Newsom's Veto Sparks Controversy Over Wildfire Insurance

Updated Category News Views 4

A Flames of Controversy Light Up California's Insurance Arena Some days, you look at the headlines and just think, "What the heck is going on here?" When Governor Gavin Newsom struck down two critical bills designed to help wildfire survivors, it wasn't just bureaucratic arm-wrestling. It landed like a gut punch to a state already licking its wounds from raging wildfires....

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Expanding Quantum Key Distribution Landscape

Updated Category News Views 167

The Potential of Quantum Key Distribution in Modern Security The global Quantum Key Distribution (QKD) market is poised for remarkable growth, projected to expand from USD 0.48 billion in 2024 to USD 2.63 billion by 2030. This growth represents a Compound Annual Growth Rate (CAGR) of 32.6%, highlighting the increasing demand for advanced data security solutions. Rising...

Continue Reading
Bryn Mawr Trust Expands Wealth Advisory Team with New Leaders

Updated Category News Views 138

Bryn Mawr Trust Welcomes New Financial Experts to Its Team Bryn Mawr Trust, a key player in the financial services landscape, is expanding its wealth advisory capabilities by welcoming three esteemed professionals. The addition of Tony Lunger as Senior Vice President and Wealth Director, Mark Gerstenschlager as Senior Vice President and Senior Investment Advisor, and...

Continue Reading
NIO Inc. Gears Up for Exciting Launch of Firefly Brand

Updated Category News Views 228

Exciting Developments at NIO Inc. NIO Inc. (NYSE: NIO) is capturing attention in the market with notable movements in its stock prices, especially evident in premarket trading sessions. Recently, NIO has been preparing to introduce its innovative sub-brand, Firefly, marking an essential step in its commitment to electric vehicles. Unveiling the Firefly Brand NIO's Firefly...

Continue Reading
GEN3 Silicon Anode Batteries Achieve 40% Capacity Increase

Updated Category News Views 84

Performance of GEN3 Silicon-Anode Lithium-Ion Batteries After undergoing 50 cycles, 18650 batteries utilizing GEN3 silicon-based materials demonstrate a remarkable 40% increase in capacity compared to traditional graphite. They also show a 25% improvement over GEN1 batteries and a 15% enhancement over GEN2 batteries, all while exhibiting no significant degradation. Key...

Continue Reading
Federal Reserve Adjusts Rate Outlook Amid Economic Changes

Updated Category News Views 233

Federal Reserve's Latest Rate Cut Decision The Federal Reserve recently made headlines by cutting interest rates by 25 basis points, marking its third rate cut this year. This decision signals a significant shift in the Fed's approach towards handling inflation and economic growth. Current Benchmark Rate and Future Projections The current benchmark rate now stands at a...

Continue Reading